# American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2017

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2017-07-31
- Accepted by EDGAR: Jul 31, 2017, 16:02 ET
- Period: 2017-06-30
- Accession: 0001564590-17-014487
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000156459017014487/avd-10q_20170630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000156459017014487/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2017-04-01 to 2017-06-30 | $43.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2017-01-01 to 2017-06-30 | $84.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | $34.3m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-01-01 to 2017-06-30 | $64.4m | us-gaap:GrossProfit |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | $6.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | $11.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $400.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2017-01-01 to 2017-06-30 | $698.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-04-01 to 2017-06-30 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2017-01-01 to 2017-06-30 | $3.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | $4.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | $7.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | $0.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-01-01 to 2017-06-30 | $0.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 29,605,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-01-01 to 2017-06-30 | 29,561,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Dividends paid | 6 months, 2017-01-01 to 2017-06-30 | $724.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2017-06-30 | $7.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $214.3m | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $425.6m | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $98.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $134.0m | us-gaap:Liabilities |
| Long-term debt | at 2017-06-30 | $26.3m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2017-06-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2017-06-30 | $291.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 43,374 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

### MANAGEMENT OVERVIEW

Overall financial performance for the quarter ended June 30, 2017 included sales of $77,905, which were up approximately 7%, as compared to sales of $72,724 for the second quarter of 2016. Our gross profit performance ended at $34,335 or 44% of sales, as compared to $31,395 or 43% of sales for the comparable quarter last year. Operating costs remained at 36% of sales in 2016 and for the three months ended June 30, 2017. Overall net income was up 33% at $0.15 per basic and diluted share as compared to $0.11 per basic and diluted share this time last year.

Financial performance for the six month period ended June 30, 2017 included improved sales and net income, as compared to the same period in 2016. Sales for the period were up approximately 4.5% to $148,578, as compared to $142,198 for the first six months of 2016. Under absorption of factory costs for the six month period reduced from 5% of sales to 4% of sales. Our gross profit performance ended at $64,419 or 43% of sales, as compared to $58,898 or 41% of sales for the comparable prior period. Operating expenses remained flat at 35% of net sales and net income improved by 28% to $0.27 per basic share and $0.26 per diluted share, as compared to $0.21 per basic and diluted share.

Net sales for our crop business were up 12% in the quarter and 6% year to date, as compared to the same periods of the prior year. This included gaining some immediate benefit from product line acquisitions concluded during early June 2017. Our non-crop business was down 14% in the three month period ended June 30, 2017 and 4% in the six month period, as compared to this time last year. The main driver for the reduction in non-crop sales relates to unusually high sales in the prior year from our pharmaceutical business as a small number of customers reacted to market concerns over benzocaine supply. Our international sales were up 8% for the three months ended June 30, 2017 and were flat for the six months ended June 30, 2017. A more detailed discussion of general market conditions and sales performance by category of products appears below.

When considering the balance sheet, as of June 30, 2017, net debt was reduced by $3,645 and $14,603, for the three months and six months, respectively. This reduction was achieved notwithstanding the funding of product line acquisitions announced during the second quarter of 2017. Debt, net of deferred loan fees, at June 30, 2017 and at December 31, 2016 were $26,348 and $40,951, respectively. At June 30, 2017 our U.S. business was debt free. Inventory ended the quarter at $126,865 including the impact of newly acquired products and $120,576 as of December 31, 2016. This compared to $151,102 at this time last year.

### RESULTS OF OPERATIONS

### Quarter Ended June 30:

| Net sales: | 2017 | 2016 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $39,442 | $30,912 | $8,530 | 28% |
| Herbicides/soil fumigants/fungicides | 16,045 | 21,093 | (5,048) | -24% |
| Other, including plant growth regulators | 10,096 | 6,331 | 3,765 | 59% |
| Total crop | 65,583 | 58,336 | 7,247 | 12% |
| Non-crop | 12,322 | 14,388 | (2,066) | -14% |
|  | $77,905 | $72,724 | $5,181 | 7% |
| Cost of sales: |  |  |  |  |
| Insecticides | $25,281 | $20,029 | $5,252 | 26% |
| Herbicides/soil fumigants/fungicides | 8,114 | 10,913 | (2,799) | -26% |
| Other, including plant growth regulators | 5,098 | 4,025 | 1,073 | 27% |
| Total crop | 38,493 | 34,967 | 3,526 | 10% |
| Non-crop | 5,077 | 6,362 | (1,285) | -20% |
|  | $43,570 | $41,329 | $2,241 | 5% |
| Gross profit: |  |  |  |  |
| Insecticides | $14,161 | $10,883 | $3,278 | 30% |
| Herbicides/soil fumigants/fungicides | 7,931 | 10,180 | (2,249) | -22% |
| Other, including plant growth regulators | 4,998 | 2,306 | 2,692 | 117% |
| Gross profit crop | 27,090 | 23,369 | 3,721 | 16% |
| Gross profit non-crop | 7,245 | 8,026 | (781) | -10% |
|  | $34,335 | $31,395 | $2,940 | 9% |
| Gross margin crop | 41% | 40% |  |  |
| Gross margin non-crop | 59% | 56% |  |  |
| Total gross margin | 44% | 43% |  |  |

| Net sales: | 2017 | 2016 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $55,760 | $51,773 | $3,987 | 8% |
| International | 22,145 | 20,951 | 1,194 | 6% |
|  | $77,905 | $72,724 | $5,181 | 7% |

The improved quarterly sales performance was driven by two primary factors. First, our cotton products generated strong sales arising from an increase in U.S. cotton acres planted (which are up about 20% in 2017) and higher anticipated pest pressure. Second, we experienced increased sales in products used on peanuts (where 2017 planted acres also increased 20%) sugar beets, sugar cane and fruits and vegetables. Partially offsetting these year-over-year increases were lower sales of our corn herbicide into the Midwest market, slower sales of soil fumigants due to wet weather at the time of application, and a decline in one of our insecticides sold in international markets.

Across our crop business, net sales of our insecticides group were up approximately 28% to end at $39,442, as compared to $30,912 during the second quarter of 2016. Within this category, net sales of our non-granular insecticides were driven by our cotton insecticide Bidrin® which posted significantly increased sales due to the increase in 2017 cotton acres, as noted above, and an anticipated increase in foliar pest pressure, as compared to extremely low infestation levels of 2016. Further, net sales of our granular soil insecticides were up 21%. This increase was due to the strong performance of our granular products across the board, including corn insecticides Aztec® and SmartChoice; Thimet® (used primarily in peanuts and sugar cane) and Counter®, which is largely used for nematode control in corn and sugar beets. The only offset to these increases was somewhat softer international sales of our Nemacur® brand.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the second quarter of 2017 declined by approximately 24% to $16,045 from $21,093 in the comparable period of 2016. Net sales of our herbicide products declined approximately 38%, due to reduced sales of our corn herbicide, Impact® resulting from competitive market conditions this year in the Midwest region. Sales of Dacthal® for use on a wide variety of high valued vegetable crops also declined in the second quarter of

2017, following very strong demand in the first quarter, as compared to 2016. As mentioned above, our soil fumigants business declined from the prior year’s second quarter due to excessively wet weather in the Western region, which inhibited the application of these liquid products. Offsetting these declines, we enjoyed increased sales of our Scepter® soybean herbicide, sold in the U.S. market, and our international products Hyvar® and Krovar®. Additionally, we posted our first sales of the newly acquired fungicide Chlorothalonil, insecticide Abamectin and herbicide Paraquat.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), net sales were up about 59%, as compared to the second quarter of 2016. Higher quarterly sales of our Folex® cotton defoliant and our growth regulator product NAA drove this performance. Additional factors were higher sales of our Metaldehyde granules, lower sales of our SmartBlock potato sprout inhibitor, and a small decline in toll manufacturing revenue during this year’s second quarter.

Our non-crop sales ended the second quarter of 2017 down 14% at $12,322, as compared to $14,388 for the same period of the prior year. Contributing factors were lower sales of our insecticide products for commercial pest control and lower quarterly sales of our pharmaceutical products. These negative factors were partially offset by revenues earned by our Envance majority owned subsidiary for exclusive right for licenses to certain natural oil products; and a year-over-year increase in our aerial-applied mosquito adulticide Dibrom.

Our international sales increased 6%, ending at $22,145, as compared to $20,951 for the second quarter of the prior year, driven by solid sales of our Hyvar and Krovar herbicides, and our Mocap insecticide, somewhat offset by the lighter sales of our Nemacur insecticide.

Our cost of sales for the second quarter of 2017 was $43,570 or 56% of sales. This compared to $41,329 or 57% of sales for the same period of 2016. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. The raw materials element of our cost of sales remained approximately flat, as compared to this time last year with increases in some raw materials approximately offset by decreases in others. Our factory costs and factory activity also remained very much in line with our performance this time last year. Finally, the Company made more sales with higher margins in 2017 primarily driven by strong market performance in some of our key markets.

Gross profit for the second quarter of 2017 improved by $2,940, or 9%, to end at $34,335, as compared to $31,395 for the second quarter of 2016. Gross margin percentage ended at 44% in the three months ended June 30, 2017, as compared to 43% in the same period of the prior year. This strong performance was primarily driven by strong raw material purchasing, methodical inventory management and favorable sales mix performance.

Operating expenses increased by $1,384 to $27,654 for the three months ended June 30, 2017, as compared to the same period in 2016. The differences in operating expenses by department are as follows:

|  | 2017 | 2016 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $6,456 | $6,353 | $103 | 2% |
| General and administrative | 10,205 | 8,389 | 1,816 | 22% |
| Research, product development and regulatory | 5,993 | 6,245 | (252) | -4% |
| Freight, delivery and warehousing | 5,000 | 5,283 | (283) | -5% |
|  | $27,654 | $26,270 | $1,384 | 5% |

- Selling expenses were approximately flat quarter over quarter ending up $103 at $6,456 for the three months ended June 30, 2017, as compared to the same period of 2016.
- General and administrative expenses increased by $1,816 to end at $10,205 for the three months ended June 30, 2017, as compared to the same period of 2016 driven by increased legal costs.
- Research, product development costs and regulatory expenses decreased by $252 to end at $5,993 for the three months ended June 30, 2017, as compared to the same period of 2016. The slight reduction related to timing on regulatory and product development studies.
- Freight, delivery and warehousing costs for the three months ended June 30, 2017 were $5,000 or 6.4% of sales as compared to $5,283 or 7.3% of sales for the same period in 2016. This improvement was primarily driven by reduced inventory levels driving overall lower warehouse costs and the mix of sales, including lower sales of our high volume bulk fumigant products, in comparison to the same period of the prior year.

Interest costs net of capitalized interest, were $400 in the three months ended June 30, 2017, as compared to $462 in the same period of 2016. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Three months ended June 30, 2017 Average Debt | Interest Expense | Interest Rate | Three months ended June 30, 2016 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $45,193 | $292 | 2.6% | $71,450 | $389 | 2.2% |
| Amortization of deferred loan fees | — | 63 | — | — | 63 | — |
| Subtotal | 45,193 | 355 | 3.1% | 71,450 | 452 | 2.5% |
| Notes payable | — | — | — | 27 | — | — |
| Amortization of other deferred liabilities | — | 7 | — | — | 9 | — |
| Other interest expense | — | 49 | — | — | 10 | — |
| Subtotal | 45,193 | 411 | 3.6% | 71,477 | 471 | 2.6% |
| Capitalized interest | — | (11) | — | — | (9) | — |
| Total | $45,193 | $400 | 3.5% | $71,477 | $462 | 2.6% |

The Company’s average overall debt for the three months ended June 30, 2017 was $45,193, as compared to $71,477 for the three months ended June 30, 2016. During the quarter, we continued to focus on managing our working capital and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.1% for the three months ended June 30, 2017, as compared to 2.5% in 2016.

Income tax expense increased by $447 to end at an expense of $1,681 for the three months ended June 30, 2017, as compared to $1,234 for the comparable period in 2016. The effective tax rate for the quarter was 26.8%, as compared to 26.5% in the same period of the prior year. Our effective tax rate increased due to a relatively stronger performance for our domestic business, which is in a higher tax rate jurisdiction, offset by an increase in excess tax benefits related to stock options. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the three months ended June 30, 2017 we recognized a loss of $69 on our investment in TyraTech. This compared to a loss of $47 recognized in the comparable period of 2016. This reflected their actual financial performance for 2016. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. At June 30, 2017, the carrying value of the Company’s investment in TyraTech was $2,073 and the quoted market value of its shareholding was $820 based on the London Stock Exchange, Alternative Investment Market (“AIM”). At June 30, 2017, the Company performed an impairment review of its investment in TyraTech and concluded that the implied decrease in value was not other than temporary and no impairment charge is required.

Non-controlling interest amounted to income of $227 in the three months ended June 30, 2017, as compared to $136 in the same period of the prior year. Non-controlling interest represents the share of net income that is attributable to the minority stockholder of our majority owned subsidiary, Envance.

Our overall net income for the three months ended June 30, 2017 was $4,304 or $0.15 per basic and diluted share, as compared to $3,246 or $0.11 per basic and diluted share in the same period of 2016.

### Six Months Ended June 30:

| Net sales: | 2017 | 2016 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $77,384 | $64,018 | $13,366 | 21% |
| Herbicides/soil fumigants/fungicides | 36,066 | 45,767 | (9,701) | -21% |
| Other, including plant growth regulators | 13,488 | 9,820 | 3,668 | 37% |
| Total crop | 126,938 | 119,605 | 7,333 | 6% |
| Non-crop | 21,640 | 22,593 | (953) | -4% |
| Total net sales | $148,578 | $142,198 | $6,380 | 4% |
| Cost of sales: |  |  |  |  |
| Insecticides | $48,825 | $42,215 | $6,610 | 16% |
| Herbicides/soil fumigants/fungicides | 18,396 | 24,761 | (6,365) | -26% |
| Other, including plant growth regulators | 6,991 | 5,575 | 1,416 | 25% |
| Total crop | 74,212 | 72,551 | 1,661 | 2% |
| Non-crop | 9,947 | 10,749 | (802) | -7% |
| Total cost of sales | $84,159 | $83,300 | $859 | 1% |
| Gross profit: |  |  |  |  |
| Insecticides | $28,559 | $21,803 | $6,756 | 31% |
| Herbicides/soil fumigants/fungicides | 17,670 | 21,006 | (3,336) | -16% |
| Other, including plant growth regulators | 6,497 | 4,245 | 2,252 | 53% |
| Gross profit crop | 52,726 | 47,054 | 5,672 | 12% |
| Gross profit non-crop | 11,693 | 11,844 | (151) | -1% |
| Total gross profit | $64,419 | $58,898 | $5,521 | 9% |
| Gross margin crop | 42% | 39% |  |  |
| Gross margin non-crop | 54% | 52% |  |  |
| Total gross margin | 43% | 41% |  |  |

| Net sales: | 2017 | 2016 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $108,004 | $101,628 | $6,376 | 6% |
| International | 40,574 | 40,570 | 4 | 0% |
| Total net sales | $148,578 | $142,198 | $6,380 | 4% |

Sales for the six months ended June 30, 2017 improved by 4.5% to end at $148,578, as compared to $142,198, this time last year. The improvement was driven by three major factors: first, our cotton products generated strong sales arising from an increase in U.S. cotton acres planted and higher anticipated pest pressure; second, we experienced increased sales in nearly all of our granular soil insecticide products; and third, our non-crop products, including our commercial pest control offerings and our mosquito adulticide, recorded higher sales for the six months ended June 30, 2017. Partially offsetting these year-over-year increases were lower sales of our corn herbicide into the Midwest market and slower sales of soil fumigants due to wet weather at the time of application.

Across our crop business, net sales of our insecticides group were up approximately 21% to end at $77,384, as compared to $64,018 during the six months ended June 30, 2016. Within this category, net sales of our non-granular insecticides were driven by our cotton insecticide Bidrin® which posted significantly increased sales due to the increase in 2017 U.S. cotton acres and an anticipated increase in foliar pest pressure, as compared to extremely low infestation levels of 2016. Further, net sales of our granular soil insecticides were up over 10%. This increase was due to the strong performance of our granular products including corn insecticides Aztec® and SmartChoice; Thimet® (used primarily in peanuts and sugar cane) and Counter®, which is largely used for nematode control in corn and sugar beets. Internationally, Mocap had a year-over-year increase, offset by softer international sales of our Nemacur® brand. Finally, we recorded initial sales of our newly acquired insecticide, Abamectin.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the six months ended June 30, 2017 declined by approximately 21% to $36,066 from $45,767 in the comparable period of 2016. During the period, we saw weaker sales of our corn herbicide, Impact®, in this year’s highly competitive market in the Midwest region. Further, as mentioned above, our soil fumigants business declined by approximately 12% from the prior year’s strong first half due to excessively wet weather in the Western United States which inhibited the application of these liquid products. Additionally, we experienced declines in sales of our

Scepter® soybean herbicide, sold in the U.S. market, and our Hyvar® and Krovar® herbicides, which are sold in international markets. Offsetting these declines were an increase in sales of Dacthal®, for use on a wide variety of high valued vegetable crops, and initial sales of the newly acquired fungicide Chlorothalonil.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), net sales were up about 37%, as compared to the first half of 2016. Higher sales of our Folex® cotton defoliant, due in part to increased cotton acres, and our growth regulator product NAA drove this performance. We also benefitted from improved sales of our Metaldehyde granules, in light of wet weather, and our SmartBlock potato sprout inhibitor.

Our non-crop sales ended the first half of 2017 down 4% at $21,640, as compared to $22,593 for the same period of the prior year. This category benefitted from higher sales of our insecticide products for commercial pest control and a year-over-year increase in our aerial-applied mosquito adulticide Dibrom. These positive factors were offset by lower half year sales of our pharmaceutical products which benefitted, in 2016, from elevated demand from customers concerned about short term product supply.

Our first half international sales ended at $40,574, as compared to $40,570 for the first six month of the prior year. This was a result of somewhat reduced sales of our Hyvar and Krovar herbicides and our Nemacur insecticide, offset by increased sales of our Mocap insecticide and a variety of other products.

Our cost of sales for the first half of 2017 ended at $84,159 or 57% of net sales. This compares to $83,300 or 59% of net sales in the same period of 2016. The decrease in cost of sales as a percentage of net sales in 2017 was primarily the result of three drivers: first, our purchasing team has achieved overall flat raw material prices; second, our manufacturing performance has improved including some minor inflation in manufacturing costs more than offset by better manufacturing output as we have continued to carefully manager inventory and output levels in our plants; and third, the Company made more sales with higher margins in 2017 primarily driven by strong market performance in some of our key markets.

Gross profit for the six months ended June 30, 2017 improved by $5,521, or 9%, to end at $64,419, as compared to $58,898 for the first half of 2016. Gross margin percentage ended at 43% in the first six months of 2017, as compared to 41% in the same period of the prior year. This strong performance was primarily driven by strong raw material purchasing, methodical inventory management and favorable sales mix performance.

Operating expenses increased by $3,462 to $52,605 for the six months ended June 30, 2017, as compared to the same period in 2016. The differences in operating expenses by department are as follows:

|  | 2017 | 2016 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $13,162 | $12,501 | $661 | 5% |
| General and administrative | 17,910 | 15,718 | 2,192 | 14% |
| Research, product development and regulatory | 11,689 | 10,794 | 895 | 8% |
| Freight, delivery and warehousing | 9,844 | 10,130 | (286) | -3% |
|  | $52,605 | $49,143 | $3,462 | 7% |

- Selling expenses increased by $661 to end at $13,162 for the six months ended June 30, 2017, as compared to the same period of 2016. The main drivers were an increase in sales and marketing activities in both our domestic and international regions.
- General and administrative expenses increased by $2,192 to end at $17,910 for the six months ended June 30, 2017, as compared to the same period of 2016, primarily driven by increased legal costs.
- Research, product development costs and regulatory expenses increased by $895 to end at $11,689 for the six months ended June 30, 2017, as compared to the same period of 2016. The main drivers were additional regulatory studies and increased business development costs primarily focused our new SIMPAS system.
- Freight, delivery and warehousing costs for the six months ended June 30, 2017 were $9,844 or 6.6% of sales as compared to $10,130 or 7.1% of sales for the same period in 2016. This improvement was primarily driven by reduced inventory levels driving overall carrying costs and the mix of sales and customer destinations in 2017 year to date, as compared to the same period of the prior year.

Interest costs net of capitalized interest were $698 in the first six months of 2017, as compared to $1,003 in the same period of 2016. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Six months ended June 30, 2017 Average Debt | Interest Expense | Interest Rate | Six months ended June 30, 2016 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $44,705 | $550 | 2.5% | $73,852 | $857 | 2.3% |
| Amortization of deferred loan fees | — | 125 | — | — | 125 | — |
| Subtotal | 44,705 | 675 | 3.0% | 73,852 | 982 | 2.7% |
| Notes payable | — | — | — | 35 | 1 | — |
| Amortization of other deferred liabilities | — | 16 | — | — | 19 | — |
| Other interest expense | — | 56 | — | — | 24 | — |
| Subtotal | 44,705 | 747 | 3.3% | 73,887 | 1,026 | 2.8% |
| Capitalized interest | — | (49) | — | — | (23) | — |
| Total | $44,705 | $698 | 3.1% | $73,887 | $1,003 | 2.7% |

The Company’s average overall debt for the six months ended June 30, 2017 was $44,705, as compared to $73,852 for the six months ended June 30, 2016. During the period, we continued to focus on managing our working capital and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.0% for the six months ended June 30, 2017, as compared to 2.7% in 2016.

Income tax expense increased by $767 to end at an expense of $3,061 for the six months ended June 30, 2017, as compared to $2,294 for the comparable period in 2016. The effective tax rate for the six months ended June 30, 2017 was 27.5%, as compared to 26.2% in the same period of the prior year. Our effective tax rate increased due to a relatively stronger performance for our domestic business, which is in a higher tax rate jurisdiction, offset by an increase in excess tax benefits related to stock options. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the six months ended June 30, 2017 we recognized a loss of $111 on our investment in TyraTech. This compared to a loss of $129 recognized in the comparable period of 2016. This reflected their actual financial performance for 2016. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets.

Non-controlling interest amounted to an income of $188 in the six months ended June 30, 2017, as compared to $289 in the same period of the prior year. Non-controlling interest represents the share of net income that is attributable to the minority stockholder of our majority owned subsidiary, Envance.

Our overall net income for the six months ended June 30, 2017 was $7,756 or $0.27 per basic and $0.26 per diluted share, as compared to $6,040 or $0.21 per basic and diluted share in the same period of 2016.

### LIQUIDITY AND CAPITAL RESOURCES

The Company generated $34,117 of cash from operating activities in the first six months of 2017, as compared to $25,490 in the same period of the prior year. This arose from the following: first, net income of $7,944 as compared to $6,329; second, non-cash depreciation, amortization of intangibles and other long term assets and discounted future liabilities generated $10,884, as compared to $10,736 in the prior year; third, stock based compensation of $2,322 as compared to $1,068 for the six months ended June 30, 2016; and fourth, other non-cash adjustments including loss from equity method investment provided a net cash inflow of $21,268, as compared to $18,215 in the same period of 2016.

As of June 30, 2017, our working capital reduced to $116,126, as compared to $130,001 at December 31, 2016. This change was mainly driven by reductions in accounts receivable. This time last year our working capital amounted to $153,866. The cash generated as a result of this reduction has been used to make product line acquisitions and to pay down debt.

During the six months ended June 30, 2017, net sales ended up 4.5% at $148,578, as compared to the same period of 2016. At June 30, 2017 accounts receivable decreased by 16%, as compared to the balance as of June 30, 2016. During the six months ended June 30, 2017 the level of accounts receivable decreased by $20,003, as compared to December 31, 2016. This change is driven by customer decisions related to timing of early pay and by the mix of sales of products, customers and regions in the period to June 30, 2017.

Inventories at June 30, 2017 ended at $126,865 ($151,102 at June 30, 2016), which was an increase of $6,289 as compared to December 31, 2016. It is normal at this point in the agricultural season to see our inventories increase as we work to supply grower demand in a timely manner. This year we continued to control inventory levels to focus on managing our working capital levels. Furthermore, in the first six months of 2017, we purchased less inventory than in the comparable period of the prior year. As of June 30, 2017, we believe our inventories are valued at the lower of cost or market.

The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th each year. During the six months ended June 30, 2017, the Company made accruals in the amount of $27,341. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. During the first six months of 2017, the Company made payments in the amount of $8,522. Payments are not generally significant in the second and third quarters of each fiscal year. During the six months ended June 30, 2016, the Company accrued $30,345 and made payments in the amount of $12,389.

Prepaid expenses at June 30, 2017 amounted to $12,609 ($13,979 at June 30, 2016) as compared to $ 11,424 at December 31, 2016. As of June 30, 2017, accounts payable amounted to $25,560 ($25,180 at June 30, 2016) as compared to $24,358 at December 31, 2016. In 2017, we improved our management of inventories and the increase in accounts payables as of June 30, 2017 is driven by increased manufacturing and sales activity, as compared to the same period of the prior year.

The Company utilized $18,505 for investing activities during the six months ended June 30, 2017, as compared to $5,236 during the same period of 2016. The Company made investments in capital expenditures in the current year, primarily focused on expanding plant capabilities. Furthermore, during the six month period, the Company contributed capital to our joint venture, Huifeng Amvac Innovation Co. Ltd, and completed four product lines acquisitions. During the same period of the prior year the Company made an investment in a Belgian Company that develops biological plant protection products that can be used for the control of pests and disease of agricultural crops and a small level of capital spending on our the manufacturing plants.

Financing activities utilized $15,989 principally used to pay down the line of credit during the six months ended June 30, 2017, as compared to $19,455 for the six months ended June 30, 2016. This included a net repayment of $14,025 against our senior credit facility, as compared to $18,850 for the same period last year. This was achieved notwithstanding the investments in product line acquisitions and as a result of cash generated by continued strong operating results and cash management. Further, the Company received $1,214 from the sale of common stock under its Employee Stock Purchase Plan, as compared to $195 for the same period of last year.

The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2017 and December 31, 2016. These are summarized in the following table:

| Long-term indebtedness ($000's) | June 30, 2017 Long-term | Total | December 31, 2016 Long-term | Total |
| --- | ---: | ---: | ---: | ---: |
| Revolving line of credit | $27,375 | $27,375 | $41,400 | $41,400 |
| Deferred loan fees | (1,027) | (1,027) | (449) | (449) |
| Net long-term debt | $26,348 | $26,348 | $40,951 | $40,951 |

As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250 million, an accordion feature of up to $100 million and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.

At June 30, 2017, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $143,182. This compares to an available borrowing capacity of $92,588 as of June 30, 2016. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, which has improved, (2) net borrowings, which have decreased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-18, *Statement of Cash Flows (Topic 230).* The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017. Based on the composition of the Company’s cash and cash equivalent, adoption of the new standard is not expected to have a material impact on our consolidated cash flows statements. The Company expects to adopt the standard for the financial year beginning January 1, 2018.

In October 2016 FASB issued ASU 2016-16, *Income Taxes (Topic 740).* Current US GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. Under the new standard, an entity is to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard does not include new disclosure requirements; however, existing disclosure requirements might be applicable when accounting for the current and deferred income taxes for an intra-entity transfer of an asset other than inventory. The new standard is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual periods. The Company has considered its activities with regard to such intra-entity transfers, does not expect the adoption of ASU 2016-16 to have a material impact on our consolidated financial statements and will adopt the standard for the financial year beginning January 1, 2018.

In August 2016, FASB issued ASU 2016-15, *Statement of Cash Flows (Topic 230).* The new standard addresses eight specific classification issues within the current practice regarding the manner in which certain cash receipts and cash payments are presented. The new standard is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company has reviewed the eight specific issues addressed and does not believe that the adoption of ASU 2016-15 will have a material impact on its statement of cash flows. Further, the Company is currently considering the possible option for early adoption. The Company expects to adopt the revised standard for the financial year beginning January 1, 2018.

In February 2016, FASB issued ASU 2016-02, *Leases*. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available. We will evaluate our operating lease arrangements to determine the impact of this amendment on the consolidated financial statements. The evaluation will include an extensive review of our leases, which are primarily related to our manufacturing sites, regional sales offices, lease vehicles, and office equipment. The ultimate impact will depend on the Company’s lease portfolio at the time the new standard is adopted. The Company expects to adopt ASU 2016-02 for the financial year beginning on January 1, 2019.

In May 2014, FASB issued ASU 2014-09, *Revenue from Contracts with Customers*. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. In March 2016, FASB issued an amendment to the standard, ASU 2016-08, to clarify the implementation guidance on principal versus agent considerations. Under the amendment, an entity is required to determine whether the nature of its promise is to provide the specified good or service itself (that is, the entity is a principal) or to arrange for that good or service to be provided by the other party (that is, the entity is an agent). In April 2016, FASB issued another amendment to the standard, ASU 2016-10, to clarify identifying performance obligations and the licensing implementation guidance, which retaining the related principles for those areas. The standard and the amendments are effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). This standard also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue and cash flows.

We have completed an initial scoping analysis of the effect of the standards to identify the revenue streams that may be affected by this ASU. The Company is evaluating if the adoption could result in a change in the timing of recognizing revenue for certain products from point in time, to over time, due to the creation of goods with no alternative use accompanied by an enforceable right to payment. The Company is continuing to evaluate the impact the adoption of this new guidance will have on these and other revenue transactions. The Company is currently evaluating which transition approach to use and assessing the effect the adoption of ASU2014-09 may have on our financial condition, results of operations or cash flows. The Company expects to adopt the new revenue recognition standard for the financial year beginning January 1, 2018.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2016, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2016.

## Market risk

As filed, 1,323 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2016 and the Company’s Form 8-K filed with the SEC on or about July 6, 2017.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,056 characters.

As of June 30, 2017, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2017, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 422 characters.

### Risk Factors

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 7, 2017. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

Filed Jul 31, 2017.
Source: SEC EDGAR, the filing index for accession 0001564590-17-014487. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
